CytomX Therapeutics (CTMX) to Release Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.23. CytomX Therapeutics had a negative return on equity of 30.70% and a net margin of 13.87%. The firm had revenue of $41.46 million during the quarter, compared to analyst estimates of $23.40 million. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Trading Down 2.6 %

NASDAQ CTMX traded down $0.04 during trading on Friday, reaching $1.31. 78,700 shares of the company’s stock were exchanged, compared to its average volume of 3,405,229. CytomX Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.85. The company’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.84. The firm has a market capitalization of $101.69 million, a PE ratio of 6.75 and a beta of 1.06.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group raised CytomX Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from $2.50 to $8.00 in a research note on Monday, May 6th. StockNews.com downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th. JPMorgan Chase & Co. raised CytomX Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Monday, April 22nd. BMO Capital Markets raised their price objective on CytomX Therapeutics from $3.25 to $3.59 and gave the company a “market perform” rating in a research note on Thursday, May 9th. Finally, Piper Sandler raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $2.25 to $3.50 in a research note on Tuesday, May 28th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.